Do Supplements Need FDA Approval? What DSHEA Really Says

Do supplements need FDA approval before selling?

No. Under DSHEA, a dietary supplement manufacturer can bring a product to market without submitting it to the FDA for pre-approval, and without proving efficacy to anyone beforehand. This is the opposite of how drugs work. A new drug needs an approved New Drug Application before a single pill ships; a new supplement needs nothing filed with the FDA at all, unless it contains a genuinely new dietary ingredient not sold before October 1994, in which case the manufacturer files a New Dietary Ingredient notification and can proceed 75 days later regardless of whether the FDA responds.

The manufacturer is legally responsible for making sure the product is safe and the label is truthful before it ships. The FDA's role is downstream: it monitors adverse event reports, can inspect manufacturing facilities, and can act against a product already on shelves if it is found to be adulterated or misbranded. It is a post-market enforcement system, not a pre-market gate. That distinction is the whole article, and almost nobody outside the industry knows it.

What does DSHEA actually regulate?

DSHEA regulates the category, not the individual product. It defines what counts as a dietary supplement, sets manufacturing standards manufacturers must follow, and fixes labeling rules — but it does not require a government review of any specific formula before sale.

Three things DSHEA does put in place matter for anyone selling or promoting in this space:

• Current Good Manufacturing Practices (cGMP) under 21 CFR Part 111 — facility-level rules covering identity testing, contamination control, and record-keeping. This is a process standard, not a product endorsement.
• Structure/function claim rules — a supplement can say it \"supports joint mobility\" or \"promotes healthy sleep\" without FDA sign-off, but the label must carry a specific disclaimer: the statement has not been evaluated by the FDA, and the product is not intended to diagnose, treat, cure, or prevent any disease.
• Adverse event reporting — manufacturers must report serious adverse events to the FDA, which is one of the few real-time signals the agency gets about a product already on the market.

None of this constitutes approval. A cGMP-compliant facility can still ship a poorly formulated product; the standard governs how it was made, not whether it works.

What claims turn a supplement into an unapproved drug?

A disease claim does. The moment marketing says a product treats, cures, prevents, mitigates, or diagnoses a specific disease — diabetes, cancer, depression, erectile dysfunction as a diagnosed condition — the FDA can classify it as an unapproved new drug, regardless of what's actually in the bottle. Structure/function language stays on the supplement side of the line; disease language crosses it.

In practice this line gets blurry fast, and VSL copy lives right on top of it. \"Supports healthy blood sugar already in normal range\" is a structure/function claim. \"Reverses type 2 diabetes\" is a drug claim wearing a supplement's packaging. The FDA has sent warning letters over exactly this pattern for years — weight loss, joint pain, and sexual health are the three verticals where it happens most often, per the agency's own warning letter archive, which publishes examples by category.

The test isn't intent, it's the words on the page and the page's implied meaning together. A testimonial saying \"my A1C dropped from 9.2 to 5.8\" attached to a supplement ad reads as a disease claim even if the brand's official copy stays cautious, because the FTC and FDA both evaluate the net impression an ad leaves, not just the literal sentence a lawyer can point to.

Why do VSLs say 'FDA-registered facility' — and what does it mean?

It means the facility submitted a registration to the FDA, as it is legally required to do if it manufactures food or supplements for U.S. distribution. It says nothing about the product. Facility registration is closer to a business license than a quality mark; the FDA does not inspect every registered facility on any regular schedule, and registration confirms the FDA knows the facility exists, not that anyone reviewed what comes out of it.

That phrase does real work in a VSL precisely because it borrows the authority of the word \"FDA\" while committing to nothing the FDA actually verified. Viewers hear \"FDA\" and \"approved\" collapses into one idea in their head, even though the script never says \"approved.\" It's a compliance-adjacent phrase engineered to survive a legal read while still producing the emotional effect of a stamp of approval. That's not necessarily deceptive on its own — the registration is real — but it is doing more persuasive work than its literal meaning supports, and offer owners know it.

Watch for these adjacent phrases doing similar work in the same VSLs:

• \"Made in an FDA-registered facility\" — registration, not inspection or approval
• \"cGMP certified\" — no independent cGMP certification body exists; this usually means self-attested compliance
• \"Clinically proven\" — check whether a study is named and linkable, or whether it's a reference to an ingredient study rather than the finished product
• \"Doctor formulated\" — says nothing about dosage, sourcing, or whether that doctor has any ongoing relationship with the brand

Who enforces supplement advertising if not the FDA?

The Federal Trade Commission handles supplement advertising claims, while the FDA handles the product itself — labeling, manufacturing, and safety. That split matters because it means two different agencies with two different enforcement postures are involved, and neither one pre-clears anything.

The FTC's authority comes from Section 5 of the FTC Act, which bars unfair or deceptive practices, and its published endorsement guides specifically cover testimonials, influencer disclosures, and the \"typical results\" problem — a testimonial showing an outlier result needs a clear disclosure of what's typical, or the ad itself is treated as making an implied efficacy claim. The FTC has pursued supplement marketers this way for over two decades, including sizable settlements against companies whose ads implied clinical backing that didn't exist.

In day-to-day terms, the entity actually stopping most bad supplement ads from running isn't a regulator at all — it's Meta and Google. Meta's advertising policies prohibit health claims that create unrealistic expectations and restrict personal health condition targeting outright; Google's healthcare and medicines policy requires certification for some categories and blocks others entirely. These platform reviews happen before an ad goes live and get applied at a scale no single federal agency reaches, which means for most affiliates the real gatekeeper on any given Tuesday is a Meta ad reviewer, not anyone in Washington.

A quick reference

What should affiliates check before promoting an offer?

Check the claims on the actual landing page and VSL script, not the brand's general reputation. A supplement brand can be legitimate and cGMP-compliant while running a VSL script that crosses into disease-claim territory, and the affiliate running traffic to it carries platform-level risk even though they didn't write the copy.

A short list worth actually running through, per offer, before spending a dollar:

• Does the VSL name a specific disease (diabetes, cancer, clinical depression) rather than a structure/function outcome?
• Are testimonials attached to numeric before/after results with no \"results not typical\" disclosure visible on screen?
• Does the landing page carry the required \"not evaluated by the FDA\" disclaimer, and is it legible rather than 6px gray-on-white?
• Has the network flagged the offer for a compliance rewrite recently — networks like ClickBank and Digistore24 push these updates fast when a script draws platform heat.
• Is the angle using a screened or fabricated \"doctor\" persona without a real, checkable credential attached?

Most affiliates skip this because it feels like the offer owner's job, and legally a lot of the direct liability does sit with the manufacturer and advertiser named in the FTC's own guidance. But ad accounts get suspended over landing page copy an affiliate never wrote, and a suspended account is a cost the checklist above is cheap against. Five minutes reading the actual page beats finding out from a policy-violation email that the account is gone.

Frequently asked questions

Do supplements need FDA approval before they can be sold?

No, supplements do not need FDA approval before sale. Under DSHEA, the manufacturer is responsible for safety and truthful labeling, and the FDA's role is limited to post-market enforcement, facility registration oversight, and acting on adverse event reports after a product is already on the market.

What does 'FDA-registered facility' actually mean on a supplement label?

It means the manufacturing facility filed a required registration with the FDA, which any U.S. food or supplement facility must do. It does not mean the FDA inspected or approved that specific product, and it is often used in VSLs to borrow regulatory-sounding credibility without claiming actual approval.

What makes a supplement claim illegal versus just borderline?

Structure/function claims (\"supports joint health\") are legal with the required FDA disclaimer. Disease claims (\"treats arthritis,\" \"reverses diabetes\") cross into unapproved-drug territory and can trigger FDA warning letters and FTC action, regardless of whether the underlying product is otherwise compliant.

Who actually enforces supplement advertising rules day to day?

In practice, Meta and Google's ad review systems catch far more non-compliant supplement ads than the FDA or FTC do, since platform policies apply pre-publication at massive scale. The FTC handles advertising deception under Section 5 of the FTC Act, but usually after the fact, not before an ad runs.

What should an affiliate check before running traffic to a supplement offer?

Read the actual VSL script and landing page for disease claims, undisclosed atypical testimonial results, and a visible FDA disclaimer, rather than trusting the brand's general reputation. Compliance risk and ad-account risk sit with the specific creative running, not the company's overall standing.

Sources

Named rather than linked — verify before relying on any figure below.

• DSHEA of 1994 (21 U.S.C. § 321 / statutory text)
• FDA Dietary Supplement Labeling Guide and cGMP rule, 21 CFR Part 111
• FTC Endorsement Guides and FTC Act Section 5 enforcement actions
• Meta Advertising Policies — Health and Wellness
• Google Ads Healthcare and Medicines policy
• FDA warning letter database (dietary supplements category)